Our portfolio company Resistell has announced a new collaboration with the Center for Research and Innovation in Clinical Pharmaceutical Sciences (CRISP) at the University Hosptial of Lausanne (CHUV).
The partnership will focus on combating multidrug-resistant bacterial lung infections, a major global health concern.
Resistell’s Phenotech instruments, which use nanomotion to measure living cells, will be tested to assess its feasibility as a diagnostic tool. This innovative approach has the potential to revolutionize the industry and provide a fast, reliable, and disruptive alternative to existing phagograms. This partnership highlights the power of bringing together academia and industry to address critical challenges in healthcare.
We look forward to seeing the impact this collaboration will have in the fight against multidrug-resistant bacterial lung infections.
More about Resistell
